Business
Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas
Compared To Synthetic Controls, INT230-6 Alone Extended Survival In Refractory Soft Tissue Sarcoma Subjects by Nearly 450 Days With Favorable Safety INT230-6,
About this update from Intensity Therapeutics, Inc.
[{"type":"text","content":"Compared To Synthetic Controls, INT230-6 Alone Extended Survival In Refractory Soft Tissue Sarcoma Subjects by Nearly 450 Days With Favorable Safety\nINT230-6, a Locally Delivered Cytotoxic Treatment Leading to a Systemic Immune Response in Hot or Cold Tumors, Is A New Way To Treat Sarcoma\nResults to be Presented Today, June 3, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting\nWESTPORT, Conn., June 3, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (\"Intensity\"), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral (IT) cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that data from its ongoing phase 1/2 clinical trial demonstrating the efficacy and tolerability of INT230-6, either as monotherapy or in combination with ipilimumab in patients with relapsed, refractory and metastatic sarcomas, will be presented this afternoon at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago and virtually from June 2-6, 2023.\nAbstract Title: Intratumoral INT230-6 (Cisplatin, Vinblastine, SHAO) alone or with ipilimumab (IPI) prolonged survival with favorable safety in adults with refractory sarcomas [Intensity IT-01; BMS#CA184-592].Presenter/First Author: Christian F. Meyer, MD, Johns Hopkins Sydney Kimmel Cancer CenterSession Title: SarcomaPoster Session Date and Time: Saturday, June 3, 2023, 1:15 PM – 4:15 PM EDTLocation: Exhibit HallAbstract Number: 11568Poster number: 502\nCopies of the presentation materials are available on Intensity's website on the publications, papers and posters page.\nSarcoma remains a very challenging cancer to treat and has historically proven resistant to checkpoint blockade. Novel approaches are needed for this patient population, and Intensity's data indicate that sarcoma is an attractive target for intratumoral injection. Christian Frederick Meyer, M.D., Ph.D., M.S. Assistant Professor of Oncology at the Sidney Kimmel Cancer Center at Johns Hopkins University is an investigator for Intensity's phase 1/2 clinical trial and the presenter of the data at ASCO. Dr. Meyer has placed a number of his sarcoma patients into the study. INT230-6 has demonstrated significant survival prolongation and continues to be of great...